Jacobi Capital Management’s Pacira BioSciences PCRX Stock Holding History

Jacobi Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-18	Closed	-$1K	–	1429
2020 Q4	$1K	Hold	18	–	–	﹤0.01%	1253
2020 Q3	$1K	Hold	18	–	–	﹤0.01%	1202
2020 Q2	$1K	Hold	18	–	–	﹤0.01%	1167
2020 Q1	$1K	Buy	+18	New	+$748	﹤0.01%	1071

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jacobi Capital Management's PCRX Position: Q1 2021 in Review

Jacobi Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2021, closing a stake of 18 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in PCRX in Q1 2020 and held it in 4 quarters. The position peaked at $1K in Q4 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

Jacobi Capital Management reported no remaining Pacira BioSciences position as of Q1 2021 after selling out during the quarter.
Jacobi Capital Management sold 18 Pacira BioSciences shares in Q1 2021, an estimated $1K.
Jacobi Capital Management first reported a position in Pacira BioSciences in Q1 2020 and held it in 4 quarters.
Jacobi Capital Management's Pacira BioSciences position peaked at $1K in Q4 2020.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on Jacobi Capital Management's 13F filing for Q1 2021, filed 11 May 2021.